期刊
JOURNAL OF ANTIBIOTICS
卷 65, 期 12, 页码 593-598出版社
JAPAN ANTIBIOTICS RESEARCH ASSOC
DOI: 10.1038/ja.2012.77
关键词
contemporary MRSA; marine actinomycete; nosiheptide; thiopeptide
资金
- National Institutes of Health (NIH) Training Program in Marine Biotechnology [T32 GM067550]
- Ruth L Kirschstein National Research Service Award (NRSA) from National Institutes of Health [5 F31 GM090658-02]
- German Research Foundation (DFG)
- National Institutes of Health grant [GM084350]
- NIH Fogerty Center International Cooperative Biodiversity Groups program [U01-TW00007-401]
The rapid rise in antimicrobial resistance in bacteria has generated an increased demand for the development of novel therapies to treat contemporary infections, especially those caused by methicillin-resistant Staphylococcus aureus (MRSA). However, antimicrobial development has been largely abandoned by the pharmaceutical industry. We recently isolated the previously described thiopeptide antibiotic nosiheptide from a marine actinomycete strain and evaluated its activity against contemporary clinically relevant bacterial pathogens. Nosiheptide exhibited extremely potent activity against all contemporary MRSA strains tested including multiple drug-resistant clinical isolates, with MIC values <= 0.25 mg l(-1). Nosiheptide was also highly active against Enterococcus spp. and the contemporary hypervirulent BI/NAP1/027 strain of Clostridium difficile but was inactive against most Gram-negative strains tested. Time-kill analysis revealed nosiheptide to be rapidly bactericidal against MRSA in a concentration- and time-dependent manner, with a nearly 2-log kill noted at 6 h at 10 x MIC. Furthermore, nosiheptide was found to be non-cytotoxic against mammalian cells at > >100 x MIC, and its anti-MRSA activity was not inhibited by 20% human serum. Notably, nosiheptide exhibited a significantly prolonged post-antibiotic effect against both healthcare- and community-associated MRSA compared with vancomycin. Nosiheptide also demonstrated in vivo activity in a murine model of MRSA infection, and therefore represents a promising antibiotic for the treatment of serious infections caused by contemporary strains of MRSA. The Journal of Antibiotics (2012) 65, 593-598; doi:10.1038/ja.2012.77; published online 10 October 2012
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据